Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JRF102
- Development stage
- Phase 2
- Lead developer
- Shenzhen Jinruijiye Biotechnology
- Modality
- Small Molecules
01
Overview
JRF102 is a small molecule inhibitor of MAPK-activated protein kinase 2 (MK2) being developed by Shenzhen Jinruijiye Biotechnology for the treatment of solid tumors. MK2 is a serine/threonine kinase that acts as a downstream effector of the p38 mitogen-activated protein kinase (MAPK) pathway, playing a critical role in the regulation of inflammatory cytokines and the cellular response to DNA damage. By inhibiting MK2, JRF102 aims to suppress tumor growth and modulate the inflammatory environment within the tumor microenvironment. The drug is currently in early-stage clinical development, with its status indicated as Preclinical/Phase 1 in the company's 2024-2026 development roadmap.
02
Targets
MK2 (Mitogen-activated protein kinase-activated protein kinase 2)
Beyond the preview
Go deeper on JRF102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JRF102.